For decades, electroconvulsive therapybetter known as ECThas been one of psychiatry’s heavy-duty tools for severe depression. It has also carried a reputation problem roughly the size of a grand piano. Modern ECT is not the frightening movie-scene treatment many people imagine; it is performed under anesthesia, carefully monitored, and often effective when standard antidepressants fail. Still, the search for faster, easier, and more tolerable treatments has continued.
Enter ketamine, the medical world’s unexpected plot twist. Once known mainly as an anesthetic, ketamine and its close relative esketamine have become serious contenders in the treatment of depression, especially treatment-resistant depression. Recent research suggests that, for some adults with nonpsychotic treatment-resistant major depression, ketamine may work at least as well as ECTand may even be preferred by some patients because of differences in memory effects, convenience, and speed of symptom relief.
But before anyone declares a winner and throws confetti in the clinic hallway, the real story is more careful: ketamine is promising, ECT is still powerful, and the best treatment depends on the patient, the diagnosis, medical history, safety needs, cost, access, and clinician judgment.
What Is Treatment-Resistant Depression?
Treatment-resistant depression usually refers to major depressive disorder that has not improved enough after trying two or more appropriate antidepressant treatments. That does not mean a person is “untreatable.” It means the first tools in the toolbox did not do the job, and the care team may need to consider a different strategy.
Depression is not just feeling sad after a rough Tuesday. It can affect sleep, appetite, energy, concentration, motivation, relationships, school or work performance, and the ability to enjoy life. Many people respond to psychotherapy, lifestyle support, antidepressant medication, or a combination of approaches. Others need more advanced options, such as medication augmentation, transcranial magnetic stimulation, ECT, ketamine, or esketamine.
The National Institute of Mental Health has reported that millions of U.S. adults experience major depressive episodes, and many receive treatment. Yet a meaningful group continues to struggle despite care. That is where the ketamine-versus-ECT conversation becomes so important.
Ketamine vs. ECT: Why the Comparison Matters
ECT has long been considered one of the most effective treatments for severe or treatment-resistant depression. During modern ECT, a patient receives anesthesia and a muscle relaxant while a controlled electrical stimulus triggers a brief therapeutic seizure. The goal is not punishment, pain, or drama. The goal is to create changes in brain activity and chemistry that can reduce severe depressive symptoms.
Ketamine works differently. It affects the brain’s glutamate system, which is involved in learning, mood regulation, and neural communication. Instead of mainly targeting serotonin or norepinephrine like many traditional antidepressants, ketamine appears to encourage more flexible brain signaling. In plain English: it may help the brain get unstuck.
This difference matters because traditional antidepressants often take weeks to show benefits. Ketamine and esketamine may act faster in some people. For someone who has spent months or years moving through treatments like a contestant in the world’s least fun obstacle course, speed can be meaningful.
The Big Study: Ketamine Was Non-Inferior to ECT
A major real-world clinical trial compared intravenous ketamine with ECT in adults who had treatment-resistant major depression without psychosis. The study found that ketamine was non-inferior to ECT, meaning it performed at least well enough compared with ECT to meet the trial’s statistical standard.
In simple terms, ketamine did not look like a second-string substitute. It looked like a serious treatment option for a specific group of patients. Reports from the trial indicated that more participants in the ketamine group experienced a treatment response than in the ECT group, although the interpretation should remain cautious because the study had limitations, including an open-label design.
The phrase “may be more effective” should therefore be handled with care. Ketamine may appear more favorable in certain measures, in certain patients, under certain study conditions. But medicine is not a boxing match with one permanent champion. ECT still has a strong record, especially in severe depression, psychotic depression, catatonia, and urgent clinical situations where a psychiatrist believes it is the best option.
Why Ketamine Is Getting So Much Attention
1. It May Work Quickly
One of ketamine’s most talked-about advantages is speed. Some patients report improvement within hours or days rather than weeks. That does not happen for everyone, and the effect may fade without a long-term treatment plan. Still, rapid improvement is one reason researchers and clinicians keep studying ketamine-based therapies.
2. It Uses a Different Brain Pathway
Many antidepressants influence serotonin, norepinephrine, or dopamine. Ketamine’s effect on glutamate gives clinicians another pathway to explore when standard treatments have not worked. Think of it like finding a side road after the highway has been closed for construction since 2017.
3. It May Have Fewer Memory-Related Side Effects Than ECT
ECT can cause confusion and memory problems, especially around the treatment period. For many people, these effects improve, but memory concerns are one of the major reasons patients hesitate. In the ketamine-versus-ECT study, cognitive outcomes were an important part of the comparison, and ketamine appeared to have advantages in some memory-related measures.
4. It May Feel Less Intimidating
ECT requires anesthesia and a procedure suite. Ketamine infusion and esketamine nasal spray also require medical supervision, but many patients perceive them as less intimidating. Perception matters. A treatment that a patient is willing to start and continue has a better chance of helping than one they avoid out of fear.
Why ECT Still Matters
It would be a mistake to write ECT’s retirement announcement. ECT remains one of the most effective treatments for severe depression, particularly when symptoms are intense, disabling, or accompanied by psychosis or catatonia. It is also a treatment with decades of clinical experience behind it.
Modern ECT is carefully performed. Patients are asleep, monitored, and supported by a medical team. Treatments are often given several times per week for a limited course, followed by maintenance treatment if needed. Many people notice improvement after multiple sessions, though response varies.
The downsides are real. ECT can cause temporary confusion, headaches, muscle aches, nausea, and memory issues. It also requires anesthesia, transportation planning, and time away from normal routines. For some patients, those trade-offs are acceptable because the benefits are substantial. For others, ketamine may be a more appealing option if clinically appropriate.
Esketamine: The FDA-Approved Ketamine-Related Option
It is important to separate ketamine from esketamine. Ketamine is FDA-approved as an anesthetic, not as a psychiatric treatment. Some clinicians use intravenous ketamine off-label for depression, but off-label use requires careful medical judgment.
Esketamine, sold as a nasal spray under the brand name Spravato, is FDA-approved for adults with treatment-resistant depression. In 2025, FDA labeling allowed esketamine to be used as monotherapy for treatment-resistant depression in adults, meaning it does not always have to be paired with an oral antidepressant. However, it is not a take-home-and-wing-it medication. It must be administered in a certified healthcare setting because of risks such as sedation, dissociation, increased blood pressure, and potential misuse.
That supervision is not bureaucratic decoration. It is part of making the treatment safer. Patients are monitored after receiving esketamine, and clinicians evaluate whether the benefits outweigh the risks.
Possible Side Effects and Safety Concerns
Ketamine and esketamine are not magic glitter. They can cause side effects such as dizziness, nausea, dissociation, sleepiness, anxiety, blood pressure increases, and a feeling of being detached from one’s surroundings. These effects are usually monitored in clinical settings, but they can be unsettling.
The FDA has also warned about compounded ketamine products, especially compounded nasal sprays, because compounded products are not FDA-approved and may carry quality, dosing, and safety concerns. This is one reason reputable clinicians emphasize medical supervision rather than casual or at-home experimentation.
ECT has a different safety profile. It can be very effective, but it involves anesthesia and may cause confusion or memory problems. Patients with certain heart conditions may need extra evaluation because blood pressure and heart rate can temporarily rise during treatment.
The bottom line: both treatments can help, and both require expert oversight. This is not a “pick one from a menu” situation. It is a medical decision.
Who Might Be a Candidate for Ketamine Instead of ECT?
A patient with treatment-resistant depression without psychosis may be considered for ketamine or esketamine if standard treatments have not helped enough. Ketamine may be especially appealing when memory concerns make ECT less desirable, when rapid symptom relief is a priority, or when a patient strongly prefers to avoid anesthesia.
However, ketamine may not be appropriate for everyone. A clinician may be cautious if a patient has uncontrolled high blood pressure, certain substance use concerns, unstable medical conditions, or symptoms that require another urgent intervention. ECT may be preferred in cases of psychotic depression, catatonia, or situations where the treating psychiatrist believes ECT has the strongest evidence for that patient’s condition.
Cost, Access, and Insurance: The Real-World Plot Twist
Even when research looks promising, real life loves to add paperwork. ECT is available in many hospital systems but may require scheduling, anesthesia clearance, transportation, and time off from school or work. Ketamine clinics vary widely in quality, price, and medical standards. Esketamine may be covered by insurance in some cases, but access depends on diagnosis, prior treatment history, provider availability, and plan rules.
Patients should ask practical questions: Is the treatment supervised by qualified medical professionals? What happens if side effects occur? How is progress measured? What is the plan after the initial treatment course? Is psychotherapy or medication management included? Depression treatment is not only about starting something; it is about building a sustainable recovery plan.
What Patients Should Ask Their Clinician
Before Choosing Ketamine or Esketamine
Patients can ask whether their depression meets criteria for treatment-resistant depression, what evidence supports ketamine or esketamine in their case, how side effects will be monitored, and what long-term maintenance plan is recommended. They should also ask whether their medical history creates any added risk.
Before Choosing ECT
Patients can ask how many treatments are expected, what kind of memory effects may occur, whether unilateral or bilateral electrode placement is being considered, how anesthesia risks are evaluated, and what support is needed after each session.
For Both Treatments
The most useful question may be: “How will we know if this is working?” Good care includes measurement. Symptom scales, sleep changes, daily functioning, family observations, and the patient’s own sense of improvement can all help guide next steps.
So, Is Ketamine Better Than ECT?
For some adults with nonpsychotic treatment-resistant depression, ketamine may be as effective as ECT and may offer advantages in speed, tolerability, and cognitive side effects. That is a big deal. It gives patients and clinicians another serious option when depression has not responded to standard care.
But “better” depends on the patient. ECT has a longer track record and remains a gold-standard treatment for some severe forms of depression. Ketamine is exciting, but it is not risk-free, not always covered, and not always durable without ongoing care.
The best answer is not “ketamine beats ECT” or “ECT beats ketamine.” The best answer is: modern depression care is becoming more personalized. That is good news. The more evidence-based options clinicians have, the more likely patients are to find a treatment that fits their symptoms, risks, values, and recovery goals.
Experience-Based Insights: What the Ketamine vs. ECT Decision Can Feel Like
For many people living with treatment-resistant depression, the decision between ketamine and ECT is not just scientific. It is emotional, practical, and deeply personal. A person may have already tried several medications, adjusted doses, waited through side effects, gone to therapy, improved for a while, and then slipped backward. By the time advanced treatments enter the conversation, patience may feel thinner than a receipt from a coffee shop.
One common experience is relief at simply having another option. Patients often describe treatment-resistant depression as feeling like every door has been checked twice. Learning about ketamine can feel like discovering a door that was hidden behind a bookshelf. It does not guarantee a happy ending, but it changes the room.
Another common experience is fear. ECT can sound intimidating because of its history and pop-culture baggage. Even when clinicians explain that modern ECT is controlled, safe, and performed under anesthesia, some patients still worry about memory. They may wonder whether they will forget important moments, lose sharpness at work, or feel unlike themselves. These concerns deserve respect, not dismissal.
Ketamine brings its own emotional questions. Some patients worry because it is a controlled substance. Others are uneasy about dissociation, the temporary feeling of being disconnected from ordinary perception. A well-run clinic prepares patients for that possibility, monitors them closely, and helps them understand that unusual sensations during treatment do not mean something has gone wrong.
Families and caregivers may also experience uncertainty. They may ask, “Why not just try another antidepressant?” or “Isn’t ECT extreme?” or “Is ketamine safe?” These are normal questions. Depression treatment often becomes easier when everyone understands the same basic facts: treatment-resistant depression is real, advanced treatments are legitimate medical options, and the goal is not to chase trends but to reduce suffering and restore function.
A practical example helps. Imagine an adult patient who has tried multiple antidepressants and psychotherapy but still cannot function well at work or maintain normal routines. The psychiatrist reviews options. ECT may offer a strong chance of improvement but requires anesthesia, transportation, and possible memory effects. Esketamine may be less intimidating and may work quickly, but it requires certified clinic visits, monitoring time, insurance approval, and follow-up planning. Neither option is casual. Both require commitment.
The most encouraging experience many patients report is not instant happiness. It is the return of small signals: answering messages, showering without bargaining with the universe, laughing at a joke, noticing music again, or making breakfast without feeling like it requires a congressional hearing. These small changes can matter. They suggest that the brain may be regaining flexibility.
Still, advanced treatments are not the whole recovery story. Patients often do best when ketamine, esketamine, or ECT is paired with ongoing psychiatric care, therapy, sleep support, healthy routines, and realistic relapse-prevention planning. The treatment may open a window; daily support helps keep the air moving.
Anyone considering ketamine or ECT should work with a licensed mental health professional and a qualified medical team. If depression feels overwhelming or unsafe, urgent support from a trusted adult, clinician, local emergency service, or crisis line can be lifesaving. No article can replace real care, but good information can make the next conversation with a doctor less confusingand sometimes that is the first step toward getting better.
Conclusion
Ketamine has changed the conversation about treatment-resistant depression. Research suggests that intravenous ketamine may be a strong alternative to ECT for adults with nonpsychotic treatment-resistant major depression, with potential advantages in speed and memory-related tolerability. Esketamine, the FDA-approved ketamine-related nasal spray, has further expanded the treatment landscape for adults who have not responded to standard antidepressants.
Yet ECT remains a proven and important treatment, especially for severe forms of depression where rapid, robust intervention is needed. The smartest takeaway is not that one treatment should replace the other. It is that depression care is becoming more flexible, more personalized, and more hopeful. For patients who have felt stuck, that is not just medical progressit is a reason to keep asking what else is possible.